United Therapeutics Corporation (NASDAQ:UTHR) Shares Sold by M&T Bank Corp

M&T Bank Corp trimmed its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 28.1% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,464 shares of the biotechnology company’s stock after selling 965 shares during the period. M&T Bank Corp’s holdings in United Therapeutics were worth $760,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in United Therapeutics by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company’s stock valued at $1,567,253,000 after acquiring an additional 32,213 shares in the last quarter. FMR LLC raised its stake in shares of United Therapeutics by 36.5% in the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company’s stock valued at $519,170,000 after purchasing an additional 393,777 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of United Therapeutics by 4.0% during the fourth quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company’s stock worth $401,184,000 after purchasing an additional 44,277 shares during the last quarter. AQR Capital Management LLC grew its stake in United Therapeutics by 0.8% in the fourth quarter. AQR Capital Management LLC now owns 975,444 shares of the biotechnology company’s stock worth $344,176,000 after purchasing an additional 7,710 shares in the last quarter. Finally, Alliancebernstein L.P. grew its stake in United Therapeutics by 28.5% in the fourth quarter. Alliancebernstein L.P. now owns 709,043 shares of the biotechnology company’s stock worth $250,179,000 after purchasing an additional 157,363 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, CFO James Edgemond sold 12,000 shares of the stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $325.37, for a total value of $3,904,440.00. Following the completion of the transaction, the chief financial officer owned 8,118 shares in the company, valued at $2,641,353.66. This represents a 59.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Nilda Mesa sold 645 shares of the firm’s stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total transaction of $187,043.55. Following the transaction, the director directly owned 4,883 shares in the company, valued at approximately $1,416,021.17. The trade was a 11.67% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 84,681 shares of company stock worth $25,261,669 over the last ninety days. 10.30% of the stock is currently owned by company insiders.

United Therapeutics Stock Up 0.7%

United Therapeutics stock opened at $297.68 on Tuesday. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $417.82. The firm has a market capitalization of $13.43 billion, a price-to-earnings ratio of 11.88, a PEG ratio of 6.46 and a beta of 0.53. The firm has a 50-day moving average price of $301.04 and a two-hundred day moving average price of $319.73.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating analysts’ consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The company had revenue of $794.40 million for the quarter, compared to analysts’ expectations of $726.82 million. During the same quarter in the previous year, the company posted $6.17 earnings per share. The business’s revenue for the quarter was up 17.2% compared to the same quarter last year. Research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of research analyst reports. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Wall Street Zen cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 2nd. UBS Group lowered their target price on shares of United Therapeutics from $410.00 to $385.00 and set a “buy” rating for the company in a research note on Monday, June 30th. Bank of America reduced their price target on shares of United Therapeutics from $321.00 to $315.00 and set a “neutral” rating on the stock in a research report on Wednesday, June 11th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a research report on Tuesday, July 8th. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $383.08.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.